BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF.OB, TSX: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that the company will be presenting at the upcoming IBC Drug Discovery & Development of Innovative Therapeutics (DDT) World Conference, being held in Boston, Massachusetts, on August 6-9.
